Shindler J S, Finnerty G T, Towlson K, Dolan A L, Davies C L, Parkes J D
Br J Clin Pharmacol. 1984 Dec;18(6):959-62. doi: 10.1111/j.1365-2125.1984.tb02571.x.
To study the absorption of levodopa and interaction with the extracerebral dopamine antagonist domperidone, 15 patients with idiopathic Parkinson's disease were given levodopa 500 mg p.o., alone, and with domperidone pre-treatment. Domperidone pretreatment (10, 20, 40 mg, p.o., i.v. or i.m.) caused a mean 12% increase in peak plasma levodopa concentration, which occurred a mean of 10 min earlier than when levodopa was given alone. Parkinsonian disability scores were improved and peak clinical response occurred 16 min earlier with domperidone than without. Domperidone slightly increases the immediate bioavailability (over 4 h) and anti-parkinsonian response to a given dose of levodopa.
为研究左旋多巴的吸收情况以及与脑外多巴胺拮抗剂多潘立酮的相互作用,对15例特发性帕金森病患者口服500毫克左旋多巴,分别单独给药以及在多潘立酮预处理后给药。多潘立酮预处理(口服、静脉注射或肌肉注射10、20、40毫克)使血浆左旋多巴峰值浓度平均升高12%,且比单独给予左旋多巴时平均提前10分钟出现。帕金森病残疾评分有所改善,多潘立酮组的临床反应峰值比未使用多潘立酮组提前16分钟出现。多潘立酮可略微增加给定剂量左旋多巴的即时生物利用度(4小时以上)和抗帕金森病反应。